Allergic Rhinitis Market Insight

DelveInsight’s ‘Allergic Rhinitis - Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The Allergic Rhinitis market report provides current treatment practices, emerging drugs, Allergic Rhinitis market share of the individual therapies, current and forecasted Allergic Rhinitis market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Allergic Rhinitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Allergic Rhinitis: Disease Understanding and Treatment Algorithm

Allergic Rhinitis Overview

Allergic Rhinitis is a condition that occurs when the body (the immune system) overreacts to something in the environment (triggers). It is caused by allergens, which are usually harmless substances but trigger an allergic reaction in some people. When the symptoms occur in late summer or early fall, some people call it hay fever. Those with rhinitis are prone to symptoms such as runny nose, sneezing, congestion, and sinus pressure. In addition, rhinitis can contribute to other problems such as asthma, sinus or ear conditions, or trouble sleeping.

 

Rhinitis is one of the most common chronic conditions for which medical care is sought. Allergic rhinitis is an IgE-mediated disorder of the nose caused by the interaction of airborne allergens with specific IgE-type antibodies on the surface of mast cells. The IgE-allergen interaction leads to the mast cell releasing and synthesizing several chemicals, which then cause the surrounding tissues to become inflamed. Typical initial symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion, although extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma are commonly associated as well. A positive correlation between the clinical history and allergen sensitization is usually enough to support the diagnosis of allergic rhinitis.

 

Allergic Rhinitis can last several weeks, longer than a cold or the flu. It does not cause fever, and the nasal discharge from hay fever is thin, watery, and clear, whereas nasal discharge from a cold or the flu tends to be thicker. Itching (mostly in the eyes, nose, mouth, throat, and skin) is common with allergic rhinitis but not with a cold or the flu. Sneezing occurs more with allergic rhinitis, and patients may even have severe sneeze attacks.

 

Allergic Rhinitis Diagnosis

Allergic rhinitis is often under-recognized owing to poor public awareness, limited access to allergologists, and confounding diagnoses, such as the common cold. Its diagnosis is made by considering a detailed history that is supported by examination findings (physical examination and, if needed, nasal endoscopy) and, if necessary, testing for allergen-specific IgE. Other tests such as nasal allergen challenge, CT scans, evaluation of nasal nitric oxide and ciliary beat frequency, nasal smears, nasal cultures, and analysis of nasal fluid for β-transferrin) may be required to include or exclude different forms of rhinitis.

 

The most common diagnostic tests for allergic rhinitis are the percutaneous skin test and the allergen-specific immunoglobulin E (IgE) antibody test. Less common diagnostic tools include nasal provocation testing, nasal cytology (e.g., blown secretions, scraping, lavage, and biopsy), nasolaryngoscopy, and intradermal skin testing. The WHO report offers limited recommendations on when to use these tests but notes that they generally are used by subspecialists or in research and do not play a role in the routine evaluation of allergic rhinitis.

 

Allergic Rhinitis Treatment

The first-line treatment of allergic rhinitis involves the avoidance of relevant allergens (e.g., house dust mites, molds, pets, pollens) and irritants (e.g., tobacco smoke). The second-generation oral antihistamines (e.g., fexofenadine [Allegra], loratadine [Claritin], cetirizine [Reactine], etc.) are the first-line pharmacological treatments recommended for all patients with allergic rhinitis. These medications are available with a prescription or over-the-counter. They work by blocking the histamine that body releases during an allergic response. Antihistamines come as pills, liquids, eye drops, nasal sprays, and inhalers. They include Loratadine (Claritin), Cetirizine (Zyrtec), Fexofenadine (Allegra), Levocetirizine (Xyzal), etc. Antihistamines can cause drowsiness.

 

Intranasal steroids are the most effective treatment for reducing nasal inflammation and improving conjunctival symptoms. In the UK, beclomethasone dipropionate and fluticasone propionate are available OTC, while fluticasone furoate and mometasone furoate are POM. Many studies have also looked at combining an intranasal corticosteroid and an oral antihistamine or leukotriene receptor antagonist, but most have concluded that combination therapy is no more effective than an intranasal corticosteroid alone. The LTRAs montelukast and zafirlukast are also effective in treating allergic rhinitis; however, they do not appear to be as effective as intranasal corticosteroids. LTRAs should be considered when oral antihistamines, intranasal corticosteroids and/or combination corticosteroid/antihistamine sprays are not well tolerated or are ineffective in controlling the symptoms of allergic rhinitis.

 

Nasal Decongestants (e.g., xylometazoline and oxymetazoline) are sympathetic receptor stimulants and cause constriction of the arterial vessels delivering blood to the nasal capacitance vessels, therefore starving them of blood. Oral decongestants (e.g., pseudoephedrine) are only weakly effective in reducing nasal obstruction but have a longer duration of up to six hours (with slow-release preparations). Allergen-specific immunotherapy is the treatment in which a patient’s immune system is rendered tolerant to an allergen by giving increasing doses of the allergen in a controlled fashion. When used correctly, it is the only treatment that can alter the disease course. There are two main routes by which immunotherapy is administered; subcutaneously and sublingually. Subcutaneous immunotherapy involves allergen injections at regular time intervals in a hospital by trained medical staff. With treatment lasting several years, patient commitment to attending hospital appointments is essential. Whereas, sublingual immunotherapy is considered to be much safer. The initial dose is given under supervision but can then be continued daily at home. However, patients should be warned against poor compliance, which is a concern with this form of immunotherapy.

Allergic Rhinitis Epidemiology

The Allergic Rhinitis epidemiology division provides insights about historical and current Allergic Rhinitis patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2020, the total prevalent cases of Allergic Rhinitis was 188.40 million cases in the 7MM which are expected to grow during the study period, i.e., 2018–2030.

 

The disease epidemiology covered in the report provides historical as well as forecasted Allergic Rhinitis epidemiology [segmented as Total Prevalent Cases of Allergic Rhinitis, Total Diagnosed Cases of Allergic Rhinitis, Total Age group-specific Cases of Allergic Rhinitis, Total Allergen-specific Cases of Allergic Rhinitis, and Total Treated Cases of Allergic Rhinitis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Allergic Rhinitis Epidemiology

  • Estimates show that the highest cases of Allergic Rhinitis in the 7MM were in Japan, followed by the United States, Germany, France, the United Kingdom, Italy, and Spain in 2020.
  • In the United States, the total number of prevalent cases of Allergic Rhinitis was 52.26 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • In the year 2020, the total prevalent cases of Allergic Rhinitis were 76.86 million cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
  • In Japan, the total number of prevalent cases of Allergic Rhinitis was 59.29 million cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

Allergic Rhinitis Drug Chapters

The drug chapter segment of the Allergic Rhinitis report encloses the detailed analysis of Allergic Rhinitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Allergic Rhinitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Allergic Rhinitis Emerging Drugs

 

REGN1908-1909 (Regeneron Pharmaceuticals)

REGN1908-1909, developed by Regeneron Pharmaceuticals, a 1:1 cocktail of two fully human IgG4 monoclonal antibodies (mAbs), REGN1908 and REGN1909, is being evaluated for the treatment of cat allergy. Both REGN1908 and REGN1909 bind to the dominant cat allergen, Fel d 1. REGN1908-1909 was invented using Regeneron's VelocImmune technology that utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies.REGN1908 and REGN1909 simultaneously bind to distinct Fel d 1 epitope and prevent Fel d 1 from binding to Fel d 1-specific IgE.

 

REGN5713-5714-5715 (Regeneron Pharmaceuticals)

REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1–specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron’s VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1 and that all three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo.

 

MG56 (Inmunotek)

MG56 is being developed by Inmunotek as allergic rhinitis caused by grass pollens. MG56 contains a mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of MTU(Mannosylated Therapeutic Units)/ml subcutaneous or sublingual. Currently it was investigated in a Phase II clinical trial starting in 2015. The purpose of the study was to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against grass pollen allergy.

 

MM09-MG01 (Inmunotek)

MM09 is a Dermatophagoides farinae/Dermatophagoides pteronyssinus allergen immunotherapy. Dermatophagoides pteronyssinus is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. MG01 is a grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne, and Dactylis glomerata). Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde. Currently, Inmunotek is developing both of these drugs, MM09 and MG01, in two trials. One trial is investigating MM09 and MG01 in combination (NCT04874714).

 

MG01 (Inmunotek)

MG01 is a grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne, and Dactylis glomerata). Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde. Currently, Inmunotek is also developing MG01 in monotherapy (NCT04891237).

Note: Detailed emerging therapies assessment will be provided in the final report.

Allergic Rhinitis Market Outlook

The management of allergic rhinitis may involve allergen avoidance, pharmacotherapy, allergen-specific immunotherapy, or a combination of all three. Pharmacologic options include intranasal corticosteroids (INSs), oral and intranasal antihistamines, intranasal chromones, oral and intranasal decongestants, oral and intranasal anticholinergic agents, and antileukotrienes. The Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines and the European Academy of Allergology and Clinical Immunology (EAACI) consensus statement note that INSs are a highly effective first-line treatment for moderate/severe or persistent AR because they relieve symptoms to a greater degree than other classes of drugs and are especially effective in controlling nasal congestion. The anti-inflammatory properties of INSs may explain their strong effect on clinical symptoms.

 

Allergen Immunotherapy (AIT) is recommended for patients with moderate to severe allergic rhinitis with/without mild to moderate asthma due to inhalant allergens. AIT is the only therapeutic method that may alter the natural course of allergy affecting both the development of new sensitizations and the clinical disease development (including deterioration of symptoms and progression of rhinitis to asthma). The predominant mechanism is dependent on the type of allergen-specific TH cells. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) were found to be equally effective in treating adult patients with allergic rhinitis.

 

The Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology has concluded that INSs are the most effective medication class for controlling allergic rhinitis symptoms. However, the surveys reviewed in a study by Dykewicz et al. (2020) have shown that only a minority of patients with allergic rhinitis use this form of therapy. For example, in one survey only 30% of respondents with severe nasal congestion and 21% of those with moderate nasal congestion used INSs (either alone or combined with another medication). Oral medications were the preferred form of therapy among respondents in another survey.

 

In the United States, intradermal titration testing is used to confirm sensitization to Hymenoptera venoms and to identify aeroallergen sensitization in patients with negative skin prick test responses. Although the specificity of intradermal testing with diluted aeroallergens is uncertain, this method is widely used to further evaluate patients with negative skin prick test responses and a convincing history of clinical sensitivity. But in Europe in general, a clinical history of intermittent or persistent allergic symptoms leads to an allergy work-up, including skin testing (mostly skin prick tests for inhalant allergens and sometimes intradermal test for Hymenoptera venoms), allergen-specific IgE detection in vitro, or both. Demonstration of IgE-mediated sensitization to the suspected allergen source with a clear relationship to clinical symptoms on allergen exposure is a prerequisite for AIT.

 

Key Findings

The Allergic Rhinitis market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Allergic Rhinitis in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 2.5%. According to the estimates, the highest market size of Allergic Rhinitis is found in the United States followed by Japan.

 

The United States Market Outlook

The total market size of Allergic Rhinitis therapies in the United States is expected to increase with a CAGR of 3.8% in the study period (2018–2030).

 

EU-5 Countries: Market Outlook

The total market size of Allergic Rhinitis therapies in EU-5 countries is expected to increase with a CAGR of 1.6% in the study period (2018–2030).

 

Japan Market Outlook

The total market size of Allergic Rhinitis therapies in Japan is expected to increase with a CAGR of 0.2% in the study period (2018–2030).

Allergic Rhinitis Pipeline Development Activities

The drugs which are in pipeline include:

  • REGN1908-1909 (Regeneron Pharmaceuticals)
  • REGN5713-5714-5715 (Regeneron Pharmaceuticals)
  • MG56 (Inmunotek)
  • MM09-MG01 (Inmunotek)
  • MG01 (Inmunotek)

Note: Detailed emerging therapies assessment will be provided in the final report.

Analyst Commentary

  • Environmental factors play an important role in the development and exacerbation of allergic rhinitis in childhood. Due to the increasing pollutants in the environment, the market of Allergic Rhinitis is expected to increase in the forecast period.
  • Market dominance of over-the-counter and generic medicines in the Allergic Rhinitis space can be observed and the possible hurdles might be the slow uptake of immunotherapies, secondary and late diagnosis of Allergic Rhinitis, and the high economic burden.
  • Among the emerging therapies, Regeneron’s REGN5713-5714-5715 and REGN1908-1909 and Inmunotek’s MM09 and MG01 appears to be the only drugs which have the potential to transform the Allergic Rhinitis market owing to impressive clinical data.

Access and Reimbursement Scenario in Allergic Rhinitis Therapies

Currently in Italy, the following medicines for immunotherapy, belonging to different allergen families, have received marketing authorization through a decentralized or mutual recognition procedure, in accordance with Directive 2001/83/EC: “Accarizax” (MA no. 043755), “Grazax” (MA no. 037610), “Oralair” (MA no. 039857), and “Ragwizax” (MA no. 045825). Other than this, only one diagnostic test device has been authorized: “T.R.U.E. Smart Practice Test “(24 haptens) (MA no. 044858).

 

In the UK, Acarizax is an unlicensed medicine, but licensed in Europe for both house dust mite allergic rhinitis and allergic asthma. The request for use will be for use in patients with house dust mite sensitization unable to achieve adequate symptom control through allergen avoidance and pharmacotherapy alone. NHS agreed to add Acarizax to the formulary as sublingual immunotherapy for treatment of house dust mite allergy. It should be prescribed by consultant and SpR immunologists only, and should be advised to remain in the hospital only. Patients should be advised of the unlicensed status of this medicine.

 

ALK Abello announced that it will be launching their new House Dust Mite (Acarizax) and Silver Birch tree pollen (Itulazax) sublingual desensitization immunotherapy vaccines (SLIT) in the UK in late 2021. This follows the highly successful Grass pollen vaccine SLIT called Grazax, which was launched about 10 years ago and has greatly improved the quality of life for thousands of hay fever sufferers ever since. Hopefully, Acarizax and Itulazax will be as highly effective as Grazax. The new products will be similar wafer-like tablets that dissolve under the tongue and are particularly safe to use. The Silver Birch vaccine may even reduce symptoms of the Oral Allergy Syndrome (OAS) that occurs when eating raw fruits, vegetables and nuts that cross-react with Silver Birch pollen. All treatments require 3 years of continuous use to get a full long-term cure of the specific allergy. All three products should then be available in high street pharmacists such as Boots.

 

In Europe, as per the ARIA guidelines, AIT is currently positioned as an additional treatment option for patients with the uncontrolled disease despite adequate pharmacotherapy. Both subcutaneous and sublingual immunotherapy (SCIT and SLIT) are available, and the selection of the optimal therapeutic approach depends on the patients’ phenotype and endotype, the patients’ preference for SCIT or SLIT, the availability of specific AIT products with proven efficacy, and the (lack of) reimbursement of AIT.

 

In France, most medications for Allergic Rhinitis are reimbursed if prescribed. For example, a long wait to consult French medical specialists encourages the quick purchase of OTC drugs during pollen seasons. French pharmacists are often well trained for offering OTC drugs: easy-to-use, inexpensive oral OAH, nasal sprays and eye drops. ENT physicians and allergists traditionally prescribe these molecules and train general practitioners also to do so. These molecules were prescribed very early by pediatricians and children of atopic families who present nasal signs.

Note: Detailed HTA assessment will be provided in the final report.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Allergic Rhinitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Allergic Rhinitis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Allergic Rhinitis Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Allergic Rhinitis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Allergic Rhinitis epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Allergic Rhinitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Allergic Rhinitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Allergic Rhinitis market.

Report Highlights

  • In the coming years, the Allergic Rhinitis market is set to change due to the upcoming therapies with novel route of administrations which are under investigation and ongoing research in the Allergic Rhinitis; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Allergic Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Allergic Rhinitis. The launch of emerging therapies will significantly impact the Allergic Rhinitis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Allergic Rhinitis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Allergic Rhinitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Allergic Rhinitis Pipeline Analysis
  • Allergic Rhinitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Allergic Rhinitis Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Allergic Rhinitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Allergic Rhinitis Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Allergic Rhinitis Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Allergic Rhinitis total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings of the market across the 7MM and which country will have the largest Allergic Rhinitis market size during the study period (2018–2030)?
  • At what CAGR, the Allergic Rhinitis market is expected to grow in the 7MM during the study period (2018–2030)?
  • What would be the Allergic Rhinitis market outlook across the 7MM during the study period (2018–2030)?
  • What would be the Allergic Rhinitis market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • Allergic Rhinitis patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration, and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Allergic Rhinitis market?

 

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of the Allergic Rhinitis?
  • What is the historical Allergic Rhinitis patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What would be the forecasted patient pool of Allergic Rhinitis in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Allergic Rhinitis?
  • Out of all the 7MM countries, which country would have the highest prevalent population of Allergic Rhinitis during the study period (2018–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2018–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Allergic Rhinitis?

 

Current Treatment Scenario and Emerging Therapies:

  • What are the current options for the treatment of Allergic Rhinitis?
  • What are the current treatment guidelines for the treatment of Allergic Rhinitis in the US, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Allergic Rhinitis?
  • How many therapies are developed by each company for the treatment of Allergic Rhinitis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Allergic Rhinitis?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic Rhinitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Allergic Rhinitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Allergic Rhinitis?
  • What is the global historical and forecasted market of Allergic Rhinitis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Allergic Rhinitis market.
  • To understand the future market competition in the Allergic Rhinitis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Allergic Rhinitis in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Allergic Rhinitis market.
  • To understand the future market competition in the Allergic Rhinitis market.

1. Key Insights

2. Report Introduction

3. Allergic Rhinitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Allergic Rhinitis in 2018

3.2. Market Share (%) Distribution of Allergic Rhinitis in 2030

4. Executive Summary of Allergic rhinitis

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of Allergic Rhinitis

6.3. Signs and Symptoms of Allergic Rhinitis

6.4. Risk Factors and Causes of Allergic rhinitis

6.5. Pathogenesis of Allergic rhinitis

6.6. Genetics of Allergic rhinitis

6.7. Complications of Allergic rhinitis

7. Diagnosis of Allergic rhinitis

7.1. Diagnostic Algorithm of Allergic rhinitis

7.2. Detailed History from the patient

7.3. Skin Test

7.4. IgE Antibody Test

7.5. Nasal Allergen Challenges (NAC)

7.6. Differential Diagnosis of Allergic Rhinitis

7.7. Diagnosis Guidelines of Allergic Rhinitis

7.7.1. American Academy of Otolaryngology–Head and Neck Surgery (2015)

7.7.2. Rhinitis 2020: A Practice Parameter

8. Treatment of Allergic Rhinitis

8.1. Treatment Algorithm of Allergic rhinitis

8.2. Allergen Avoidance

8.3. Antihistamines

8.4. Intranasal steroids

8.5. Corticosteroid/Antihistamine Combination Therapy

8.6. Leukotriene receptor antagonists (LTRAs)

8.7. Nasal Decongestants

8.8. Oral Decongestants

8.9. Immunotherapy

8.10. Treatment Guidelines of Allergic Rhinitis

8.10.1. American Academy of Otolaryngology–Head and Neck Surgery (2015)

8.10.2. ARIA guideline 2019: Treatment of Allergic Rhinitis in the German Health System

8.10.3. BSACI Guideline for the Diagnosis and Management of Allergic and Nonallergic Rhinitis (2017)

9. Conclusion

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Epidemiology of Allergic Rhinitis

10.3. Epidemiology Scenario

10.3.1. Total Prevalent Cases of Allergic Rhinitis

10.3.2. Total Diagnosed Cases of Allergic Rhinitis

10.3.3. Total Age group-specific Cases of Allergic Rhinitis

10.3.4. Total Allergen-specific Cases of Allergic Rhinitis

10.3.5. Total Treated Cases of Allergic Rhinitis

11. Patient Journey

12. Key Endpoints in Allergic Rhinitis Clinical Trials

13. Marketed Therapies

13.1. Zolea (Omalizumab): Novartis Pharmaceuticals

13.1.1. Drug Description

13.1.2. Regulatory Milestones

13.1.3. Other Developmental Activities

13.1.4. Pivotal Clinical Trial

13.2. Odactra/Acarizax/Miticure (House dust mite allergy immunotherapy [HDM SLIT-tablet]): ALK-Abello

13.2.1. Drug Description

13.2.2. Regulatory Milestones

13.2.3. Other Developmental Activities

13.2.4. Pivotal Clinical Trial

13.2.5. Ongoing Current Pipeline Activity

13.3. Grastek/Grazax (Grass pollen allergy vaccine tablet): ALK-Abello

13.3.1. Drug Description

13.3.2. Regulatory Milestones

13.3.3. Other Developmental Activities

13.3.4. Pivotal Clinical Trial

13.3.5. Ongoing Current Pipeline Activity

13.4. Itulazax (SQ tree SLIT-tablet): ALK-Abello

13.4.1. Drug Description

13.4.2. Regulatory Milestones

13.4.3. Other Developmental Activities

13.4.4. Pivotal Clinical Trial

13.4.5. Ongoing Current Pipeline Activity

13.5. Ragwitek/Ragwizax (Short Ragweed Pollen Allergen Extract): ALK-Abello

13.5.1. Drug Description

13.5.2. Regulatory Milestones

13.5.3. Other Developmental Activities

13.5.4. Pivotal Clinical Trial

13.6. Cedarcure (Japanese Cedar Pollen SLIT/ TO-206): Torii Pharmaceutical/ALK-Abello

13.6.1. Drug Description

13.6.2. Regulatory Milestones

13.6.3. Other Developmental Activities

13.6.4. Pivotal Clinical Trial

13.7. Cedartolen (TO-194SL): Torii Pharmaceutical

13.7.1. Drug Description

13.7.2. Regulatory Milestones

13.7.3. Other Developmental Activities

13.7.4. Pivotal Clinical Trial

13.8. Actair (STG320): Stallergenes Greer

13.8.1. Drug Description

13.8.2. Regulatory Milestones

13.8.3. Other Developmental Activities

13.8.4. Pivotal Clinical Trial

13.9. Oralair: Stallergenes Greer

13.9.1. Drug Description

13.9.2. Regulatory Milestones

13.9.3. Other Developmental Activities

13.9.4. Pivotal Clinical Trial

13.10. Bilaxten/Bilanoa (Bilastine): FAES Farma/Taiho Pharmaceuticals

13.10.1. Drug Description

13.10.2. Regulatory Milestones

13.10.3. Other Developmental Activities

13.10.4. Pivotal Clinical Trial

13.11. Pollinex Quattro (PQ): Allergy Therapeutics

13.11.1. Drug Description

13.11.2. Regulatory Milestones

13.11.3. Other Developmental Activities

13.11.4. Pivotal Clinical Trial

13.11.5. Ongoing Current Pipeline Activity

14. Emerging Therapies

14.1. Dupixent (dupilumab): Regeneron Pharmaceuticals

14.1.1. Product Description

14.1.2. Other Developmental Activities

14.1.3. Clinical Developmental Activities

14.1.4. Safety and Efficacy

14.2. AOB201 (B 244): AOBiome

14.2.1. Product Description

14.2.2. Other Developmental Activities

14.2.3. Clinical Developmental Activities

14.2.4. Safety and Efficacy

14.3. Norketotifen (NKT): Emergo Therapeutics

14.3.1. Product Description

14.3.2. Other Developmental Activities

14.3.3. Clinical Developmental Activities

14.4. REGN5713-5714-5715: Regeneron Pharmaceuticals

14.4.1. Product Description

14.4.2. Other Developmental Activities

14.4.3. Clinical Developmental Activities

14.5. REGN1908-1909: Regeneron Pharmaceuticals

14.5.1. Product Description

14.5.2. Other Developmental Activities

14.5.3. Clinical Developmental Activities

14.5.4. Safety and Efficacy

14.6. MM09-MG01: Inmunotek

14.6.1. Product Description

14.6.2. Clinical Developmental Activities

14.6.3. MG01: Inmunotek

14.6.4. Product Description

14.6.5. Clinical Developmental Activities

15. Allergic Rhinitis: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Outlook

15.3. Market of Allergic Rhinitis

15.4. Market Size of Allergic Rhinitis

15.4.1. Total Market Size of Allergic Rhinitis

15.4.2. Market Size of Allergic Rhinitis by Therapies

16. Market Access and Reimbursement

16.1. Key HTA decisions for Allergic Rhinitis

16.2. Reimbursement

16.3. Patient Access Programs

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Summary of Allergic Rhinitis, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Total Prevalent Cases of Allergic Rhinitis (in Millions) in the 7MM (2018–2030)

Table 3: Total Diagnosed Cases of Allergic Rhinitis (in Millions) in the 7MM (2018–2030)

Table 4: Total Age group-specific Cases of Allergic Rhinitis (in Millions) in the 7MM (2018–2030)

Table 5: Total Allergen-specific Cases of Allergic Rhinitis (in Millions) in the 7MM (2018–2030)

Table 6: Total Treated Cases of Allergic Rhinitis (in Millions) in the 7MM (2018–2030)

Table 7: Odactra/Acarizax/Miticure (House dust mite allergy immunotherapy [HDM SLIT-tablet]); Clinical Trial Description, 2021

Table 8: Grastek/Grazax (Grass pollen allergy vaccine tablet); Clinical Trial Description, 2021

Table 9: Itulazax (SQ tree SLIT-tablet); Clinical Trial Description, 2021

Table 10: Cedartolen recommended doses

Table 11: Dosage for Adults and Children for the Days 1-3 (and following)

Table 12: PQ Grass (Pollinex Quattro), Clinical Trial Description, 2021

Table 13: Dupixent (dupilumab), Clinical Trial Description, 2021

Table 14: B244, Clinical Trial Description, 2021

Table 15: Norketotifen, Clinical Trial Description, 2021

Table 16: REGN5713-5714-5715, Clinical Trial Description, 2021

Table 17: REGN1908-1909, Clinical Trial Description, 2021

Table 18: MM09-MG01, Clinical Trial Description, 2021

Table 19: MG01, Clinical Trial Description, 2021

Table 20: 7MM Market Size of Allergic Rhinitis in USD Million (2018–2030)

Table 21: 7MM Market Size of  Allergic Rhinitis by Therapies in USD Million (2018–2030)

Table 22: Key HTA Decisions

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Understanding of Allergic rhinitis

Figure 3: Classification of Allergic rhinitis

Figure 4: Types of Allergic rhinitis

Figure 5: Sign and Symptoms of Allergic rhinitis

Figure 6: Causes of Allergic rhinitis

Figure 7: Pathogenesis of Allergic rhinitis

Figure 8: Complications of Allergic rhinitis

Figure 9: Diagnostic Algorithm of Allergic rhinitis

Figure 10: Skin Prick Test

Figure 11: Nasal Allergen Challenges (NAC)

Figure 12: Treatment Algorithm of Allergic rhinitis

Figure 13: Intranasal steroids

Figure 14: Sublingual and Subcutaneous Immunotherapy

Figure 15: Recommendations for Adding a Second Medication to Treat Allergic rhinitis

Figure 16: Total Prevalent Cases of Allergic Rhinitis in the 7MM (2018–2030)

Figure 17: Total Diagnosed Cases of Allergic Rhinitis in the 7MM (2018–2030)

Figure 18: Total Allergen-specific Cases of Allergic Rhinitis in the 7MM (2018–2030)

Figure 19: Total Treated Cases of Allergic Rhinitis in the 7MM (2018–2030)

Novartis Pharmaceuticals
ALK-Abello
Torii Pharmaceutical
Stallergenes Greer
FAES Farma
Taiho Pharmaceuticals
Allergy Therapeutics
Regeneron Pharmaceuticals
AOBiome
Emergo Therapeutics
Inmunotek

 

Forward to Friend

Need A Quote